DK0489032T3 - Hydroxaminsyre-baserede kollagenaseinhibitorer - Google Patents

Hydroxaminsyre-baserede kollagenaseinhibitorer

Info

Publication number
DK0489032T3
DK0489032T3 DK90911398.7T DK90911398T DK0489032T3 DK 0489032 T3 DK0489032 T3 DK 0489032T3 DK 90911398 T DK90911398 T DK 90911398T DK 0489032 T3 DK0489032 T3 DK 0489032T3
Authority
DK
Denmark
Prior art keywords
hydroxamic acid
collagenase inhibitors
based collagenase
disease
involving
Prior art date
Application number
DK90911398.7T
Other languages
Danish (da)
English (en)
Inventor
Alan Hornsby Davidson
Michael John Crimmin
Colin Campion
Jonathan Philip Dickens
Original Assignee
British Bio Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Bio Technology filed Critical British Bio Technology
Application granted granted Critical
Publication of DK0489032T3 publication Critical patent/DK0489032T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK90911398.7T 1989-08-24 1990-07-20 Hydroxaminsyre-baserede kollagenaseinhibitorer DK0489032T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898919251A GB8919251D0 (en) 1989-08-24 1989-08-24 Compounds

Publications (1)

Publication Number Publication Date
DK0489032T3 true DK0489032T3 (da) 1995-01-30

Family

ID=10662057

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90911398.7T DK0489032T3 (da) 1989-08-24 1990-07-20 Hydroxaminsyre-baserede kollagenaseinhibitorer

Country Status (16)

Country Link
US (2) US5453438A (fr)
EP (1) EP0489032B1 (fr)
JP (1) JP2871849B2 (fr)
KR (1) KR927003624A (fr)
AT (1) ATE111443T1 (fr)
AU (1) AU639706B2 (fr)
CA (1) CA2064786A1 (fr)
DE (1) DE69012575T2 (fr)
DK (1) DK0489032T3 (fr)
ES (1) ES2063975T3 (fr)
FI (1) FI920771A0 (fr)
GB (1) GB8919251D0 (fr)
NO (1) NO920702L (fr)
NZ (1) NZ235050A (fr)
TW (1) TW202456B (fr)
WO (1) WO1991002716A2 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5268384A (en) * 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
EP0520573A1 (fr) * 1991-06-27 1992-12-30 Glaxo Inc. Dérivés d'imides cycliques
EP0634998B1 (fr) * 1992-04-07 1997-03-19 British Biotech Pharmaceuticals Limited Inhibiteurs de la collagenase et de la cytokine a base d'acide hydroxamique
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5326760A (en) * 1992-06-29 1994-07-05 Glaxo, Inc. Aminobutanoic acid compounds having metalloprotease inhibiting properties
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
CA2158352A1 (fr) * 1993-03-16 1994-09-29 Michael John Crimmin Derives de l'acide hydroxamique utilises comme inhibiteurs de la metalloproteinase
DE69419473T2 (de) * 1993-04-27 2000-03-16 Celltech Therapeutics Ltd. Peptidylderivate als inhibitoren von metalloproteinase
GB9308695D0 (en) * 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
ES2075797B1 (es) * 1993-08-18 1996-05-16 British Bio Technology Derivados de acidos hidroxamicos terapeuticamente activos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y el uso de dichos compuestos en medicina.
ES2075798B1 (es) * 1993-08-18 1996-03-01 British Bio Technology Derivados de aminoacidos naturales como inhibidores de metaloproteinasas, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y el uso de dichos compuestos en medicina.
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
EP0822186B1 (fr) * 1994-01-20 2000-03-15 British Biotech Pharmaceuticals Limited L-tertiaire-leucine-2-pyridylamide
GB9501737D0 (en) * 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
US5840698A (en) * 1994-10-27 1998-11-24 Affymax Technologies N.V. Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use
US5831004A (en) * 1994-10-27 1998-11-03 Affymax Technologies N.V. Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5639746A (en) * 1994-12-29 1997-06-17 The Procter & Gamble Company Hydroxamic acid-containing inhibitors of matrix metalloproteases
US5919940A (en) * 1995-01-20 1999-07-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
HUP9903863A3 (en) 1995-11-23 2000-11-28 British Biotech Pharm Metalloproteinase inhibitors
CZ62899A3 (cs) * 1996-08-28 1999-07-14 The Procter & Gamble Company 1,3-Diheterocyklické metaloproteázové inhibitory
ATE272062T1 (de) * 1996-08-28 2004-08-15 Procter & Gamble Spirocyclisch metalloprotease inhibitoren
JP3539736B2 (ja) * 1996-08-28 2004-07-07 ザ プロクター アンド ギャンブル カンパニー 基質メタロプロテアーゼインヒビターとしてのホスフィン酸アミド
AU731319B2 (en) * 1996-08-28 2001-03-29 Procter & Gamble Company, The Heterocyclic metalloprotease inhibitors
HUP0000210A3 (en) 1996-08-28 2001-07-30 Procter And Gamble Co Cincinna Heterocyclic compounds as metalloprotease inhibitors and use of them for producing pharmaceutical compisitions
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
EP0925278B1 (fr) 1996-09-10 2002-07-17 British Biotech Pharmaceuticals Limited Derives cytostatiques d'acide hydroxamique
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
EP1009737A2 (fr) 1997-07-31 2000-06-21 The Procter & Gamble Company Inhibiteurs de metalloprotease acycliques
GB9810464D0 (en) * 1998-05-16 1998-07-15 British Biotech Pharm Hydroxamic acid derivatives
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
WO2000051975A1 (fr) 1999-03-03 2000-09-08 The Procter & Gamble Company Inhibiteurs de metalloproteases, contenant alcenyle et alcynale
US6846825B1 (en) 1999-08-10 2005-01-25 British Biotech Pharmaceuticals Limited Antibacterial agents
GB9929527D0 (en) * 1999-12-14 2000-02-09 Smithkline Beecham Plc Novel compounds
US6797820B2 (en) * 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
ES2283589T3 (es) 2001-06-15 2007-11-01 Vicuron Pharmaceuticals, Inc. Compuestos biciclicos de pirrolidina.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105789A (en) * 1976-05-10 1978-08-08 E. R. Squibb & Sons, Inc. Carboxyalkylacylamino acids
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4499079A (en) * 1982-11-18 1985-02-12 E. R. Squibb & Sons, Inc. Carboxy and substituted carboxy alkanoyl and cycloalkanoyl peptides
US4496540A (en) * 1982-12-30 1985-01-29 Biomeasure, Inc. Therapeutic compounds
JPS6115840A (ja) * 1984-07-03 1986-01-23 Microbial Chem Res Found 免疫賦活剤
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes

Also Published As

Publication number Publication date
DE69012575D1 (de) 1994-10-20
JPH05501864A (ja) 1993-04-08
US5910609A (en) 1999-06-08
JP2871849B2 (ja) 1999-03-17
DE69012575T2 (de) 1995-03-30
WO1991002716A2 (fr) 1991-03-07
EP0489032B1 (fr) 1994-09-14
AU639706B2 (en) 1993-08-05
ES2063975T3 (es) 1995-01-16
FI920771A0 (fi) 1992-02-21
NO920702L (no) 1992-04-23
GB8919251D0 (en) 1989-10-04
CA2064786A1 (fr) 1991-02-25
KR927003624A (ko) 1992-12-18
NO920702D0 (no) 1992-02-21
NZ235050A (en) 1991-12-23
WO1991002716A3 (fr) 1991-06-27
EP0489032A1 (fr) 1992-06-10
TW202456B (fr) 1993-03-21
AU6045490A (en) 1991-04-03
US5453438A (en) 1995-09-26
ATE111443T1 (de) 1994-09-15

Similar Documents

Publication Publication Date Title
DK0489032T3 (da) Hydroxaminsyre-baserede kollagenaseinhibitorer
DE69734661D1 (de) Foerderung der wundheilung durch chemisch modifizierte tetracycline
ES2063334T3 (es) Inhibidores de la colagenasa basados en el acido hidroxamico.
DE50002293D1 (de) Verwendung von csf-1-inhibitoren
ATE319447T1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
ES2148229T3 (es) Eteres y tioeteres en la posicion 17 de 4-aza-esteroides.
DK1030836T3 (da) Hydroxam- og carboxylsyrederivater der har MMP- og TNF-inhiberende aktivitet
CY1105501T1 (el) Συνδυασμοι φαρμακων (π.χ. chlorpromazine και pentamidine) για την αντιμετωπιση νεοπλαστικων διαταραχων
CY1110521T1 (el) Υποκατεστημενα ινδολια για τη διαμορφωση της nfkb-ενεργοτητας
ES2133785T3 (es) Inhibidores de metaloproteinasas.
NO911962L (no) Hydroksaminsyrebaserte kollagenaseinhibitorer.
ATE191472T1 (de) Neuartige metalloprotease-inhibitoren und diese enthaltende pharmazeutische zusammensetzungen
TR200101905T2 (tr) Endotelin ile ilgili hastalıkların tedavisinde kullanılan sülfanoamidler.
ES2125276T3 (es) Tratamiento de acne o de pseudofolliculitis barbae
EA199900542A1 (ru) Соединения сульфоновой кислоты или сульфониламино-n-(гетероаралкил)-азагетероциклиламида
EA200000921A1 (ru) Антагонисты рецептора витронектина
EA199700381A1 (ru) Диароматические соединения пропинила или диенила, промежуточные соединения, фармацевтические и косметические композиции на основе указанных соединений и применение косметических композиций
DE69419954D1 (de) Arzneimittel zur Behandlung von Hauterkrankungen
DK0588477T3 (da) Medicinsk præparat omfatende TCF-11
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
DE69828638D1 (de) Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität
RU94014833A (ru) Средство для лечения дегенеративных заболеваний суставов и околосуставных тканей
ATE329613T1 (de) Wachstumhormone inhibitoren enthaltende pharmazeutische zubereitungen oder ihre biologisch aktive fragmente zur behandlung von uterinen myomas
NO20082299L (no) Anvendelse av et pleuromutilinderivat innen veterinaermedisin samt fremgangsmate for fremstilling av et medikament omfattende forbindelsen
RU94016406A (ru) Способ лечения рожистого воспаления